Related Experiment Video
Updated: May 19, 2026
06:51
Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry
Published on: November 14, 2025
High-content multiplexed tissue imaging and quantification for cancer drug discovery
Beverly L Falcon1, Julie Stewart, Scharri Ezell
1Eli Lilly and Company, Department of Cancer Angiogenesis, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Drug Discovery Today
|September 5, 2012
Summary
This study introduces a high-content immunohistochemistry (IHC) method for quantifying tumor phenotypes. This approach aids cancer drug discovery by detailing drug effects on angiogenesis, hypoxia, proliferation, and apoptosis in vivo.
Area of Science:
- Oncology
- Cancer Therapeutics
- Drug Discovery
Background:
- Targeting multiple cancer hallmarks with drug combinations is a promising therapeutic strategy.
- Understanding the in vivo mechanisms of action for single agents and combinations requires phenotypic quantification.
- Traditional immunohistochemistry (IHC) methods are not suitable for high-throughput drug discovery.
Purpose of the Study:
- To develop a high-content IHC method for quantifying key tumor phenotypes.
- To enable a deeper understanding of cancer drug mechanisms of action.
- To facilitate high-throughput analysis in cancer drug discovery.
Main Methods:
- Development of a high-content method utilizing immunohistochemistry (IHC).
- Quantification of tumor angiogenesis, vascular normalization, hypoxia, tumor cell proliferation, and apoptosis.
- Application of the method to quantify phenotypic changes in tumor models.
Main Results:
- The described high-content IHC method allows for quantitative assessment of multiple tumor phenotypes.
- This method increases understanding of tumor models and their responses to therapeutic interventions.
- Novel mechanisms of action for cancer therapeutics can be elucidated.
Conclusions:
- A high-content IHC method provides a powerful tool for phenotypic quantification in cancer research.
- This approach is valuable for advancing high-throughput cancer drug discovery.
- Improved understanding of drug efficacy and mechanisms in vivo is achievable.
